New Technology Makes Tumor Eliminate Itself

Inside the tumor: A piece of the tumor was made transparent and scanned in 3D. The components labeled with fluorescent colors were rendered in a 3D representation on the computer (red: blood vessels, turquoise: tumor cells, yellow: therapeutic antibody).
Credit: Plückthun Lab

A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could re-duce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs.

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells. Once inside tumor cells, the delivered genes serve as a blueprint for therapeutic antibodies, cytokines and other signaling substances, which are produced by the cancer cells themselves and act to elimi-nate tumors from the inside out.

Sneaking adenoviruses past the immune system undetected

“We trick the tumor into eliminating itself through the production of anti-cancer agents by its own cells,” says postdoctoral fellow Sheena Smith, who led the development of the delivery approach. Research group leader Andreas Plückthun explains: “The therapeutic agents, such as therapeu-tic antibodies or signaling substances, mostly stay at the place in the body where they’re needed instead of spreading throughout the bloodstream where they can damage healthy organs and tissues.”

The UZH researchers call their technology SHREAD: for SHielded, REtargetted ADenovirus. It builds on key technologies previously engineered by the Plückthun team, including to direct ade-noviruses to specified parts of the body to hide them from the immune system.

High amount of drugs in the tumor, low concentration in other tissues

With the SHREAD system, the scientists made the tumor itself produce a clinically approved breast cancer antibody, called trastuzumab (Herceptin®), in the mammary of a mouse. They found that, after a few days, SHREAD produced more of the antibody in the tumor than when the drug was injected directly. Moreover, the concentration in the bloodstream and in other tissues where side effects could occur were significantly lower with SHREAD. The scientists used a very sophisticated, high-resolution 3D imaging method and tissues rendered totally transparent to show how the therapeutic antibody, produced in the body, creates pores in blood vessels of the tumor and destroys tumor cells, and thus treats it from the inside.

Use to combat Covid-19 being investigated

Plückthun, Smith and colleagues emphasize that SHREAD is applicable not only for the fight against breast cancer. As healthy tissues no longer come into contact with significant levels of the therapeutic agent, it is also applicable for delivery of a wide range of so-called biologics – power-ful protein-based drugs that would otherwise be too toxic.

In fact, members of the Plückthun group are currently applying their technology in an SNF-funded project aimed as a therapy for Covid-19. Adenoviral vectors are already being used in several of the COVID vaccines, including the Johnson & Johnson, AstraZeneca, China’s CanSino Biologics and Russia’s Sputnik V vaccines – but without the innovative SHREAD technology. “By delivering the SHREAD treatment to patients via an inhaled aerosol, our approach could allow targeted production of Covid antibody therapies in lung cells, where they are needed most,” Smith ex-plains. “This would reduce costs, increase accessibility of Covid therapies and also improve vac-cine delivery with the inhalation approach.”

Funding:
This work was supported by Swiss National Science Foundation (Sinergia Grant 170929) and National Cancer Institute of the NIH (F32CA189372).
The ongoing COVID project is supported by Swiss National Science Foundation (NRP78, 198287).

Wissenschaftliche Ansprechpartner:

Prof. Dr. Andreas Plückthun
Biochemisches Institut
Universität Zürich
Telefon: +41 44 635 55 70
plueckthun@bioc.uzh.ch

Originalpublikation:

Smith, S. N., Schubert, R., Brücher, D., Simic, B., Schmid, M., Kirk, N., Freitag, P., Gradinaru, V. and Plückthun, A.The SHREAD gene therapy platform for paracrine delivery improves tumor local-ization and intratumoral effects of a clinical antibody as shown by PACT. PNAS. 17 May 2021. DOI: 10.1073/pnas.2017925118

http://www.uzh.ch/

Media Contact

Rita Ziegler Kommunikation
Universität Zürich

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

World’s smallest molecular machine

… reversible sliding motion in ammonium-linked ferrocene. Researchers stabilized ferrocene molecules on a flat substrate for the first time, creating an electronically controllable sliding molecular machine. Artificial molecular machines, nanoscale…

Towards the control of chemical reactions

Overcoming one of the challenges of quantum mechanics: A major result in quantum mechanics has been achieved: for the first time, the temporal evolution of a quantum system has been…

Planets form through domino effect

New radio astronomy observations of a planetary system in the process of forming show that once the first planets form close to the central star, these planets can help shepherd…